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ABSTRACT
Background and aims Having anecdotally noted a 
high frequency of lobar- restricted cerebral microbleeds 
(CMBs) mimicking cerebral amyloid angiopathy (CAA) in 
patients with previous cardiac surgery (especially valve 
replacement) presenting to our transient ischaemic 
attack (TIA) clinic, we set out to objectively determine 
the frequency and distribution of microbleeds in this 
population.
Methods We performed a retrospective comparative 
cohort study in consecutive patients presenting to two 
TIA clinics with either: (1) previous coronary artery bypass 
grafting (CABG) (n=41); (2) previous valve replacement 
(n=41) or (3) probable CAA (n=41), as per the Modified 
Boston Criteria, without prior cardiac surgery. Microbleed 
number and distribution was determined and compared.
Results At least one lobar- restricted microbleed was 
found in the majority of cardiac surgery patients (65%) 
and 32/82 (39%) met diagnostic criteria for CAA. Valve 
replacement patients had a higher microbleed prevalence 
(90 vs 51%, p<0.01) and lobar- restricted microbleed 
count (2.6±2.7 vs 1.0±1.4, p<0.01) than post- CABG 
patients; lobar- restricted microbleed count in both groups 
was substantially less than in CAA patients (15.5±20.4, 
p<0.01). In postcardiac surgery patients, subcortical white 
matter (SWM) microbleeds were proportionally more 
frequent compared with CAA patients. Receiver operator 
curve analysis of a ‘location- based’ ratio (calculated as 
SWM/SWM+strictly- cortical CMBs), revealed an optimal 
ratio of 0.45 in distinguishing cardiac surgery- associated 
microbleeds from CAA (sensitivity 0.56, specificity 0.93, 
area under the curve 0.71).
Conclusion Lobar- restricted microbleeds are common 
in patients with past cardiac surgery, however a higher 
proportion of these CMBs involve the SWM than in patients 
with CAA.
INTRODUCTION
Cerebral microbleeds (CMBs) are small peri-
vascular haemosiderin deposits detectable 
on blood sensitive MRI sequences. They 
commonly represent a radiologic marker of 
cerebral small vessel disease. Among the most 
common causes of CMBs is cerebral amyloid 
angiopathy (CAA).1 2 The pattern of CMB 
distribution is important for determining 
underlying vascular pathology and in turn risk 
of intracerebral haemorrhage (ICH), since 
CAA is associated with the highest bleeding 
risk.3 This is especially relevant for decided 
antithrombotics treatments and determining 
thrombolysis risk should ischaemic stroke 
occur.1 4 5
It has been suggested that cortical/subcor-
tical predominant CMBs can develop acutely 
postcardiac surgery, such as in the setting 
of valve replacement and coronary artery 
bypass grafting (CABG).6–8 These findings, 
if persisting chronically, provide a diagnostic 
challenge as a ‘lobar’ pattern of microbleed 
distribution mimics that seen in CAA and 
may fulfil the Modified Boston Criteria for 
‘probable CAA’. This could lead to inappro-
priate cessation of antithrombotic therapy 
or avoidance of reperfusion treatments in 
patients whose microbleeds are secondary to 
cardiac surgery, rather than underlying CAA.
We have observed through our neurovas-
cular services several patients with ‘lobar- 
restricted’ microbleeds and a history of 
cardiac surgery. Longitudinal imaging did 
not show increasing microbleed burden, 
suggesting a chronic pattern.
Aims
We, therefore, set out to systematically investi-
gate the incidence and distribution of CMBs in 
patients presenting to our transient ischaemic 
attack (TIA) clinics with a history of cardiac 
surgery (with and without valve surgery) and 
those without cardiac surgery but meeting 
‘probable’ CAA diagnostic criteria, in order 




We performed a retrospective two- centre 
cohort study of 2022 consecutive patients 
presenting to the TIA clinic at the Royal 
Adelaide Hospital and Lyell McEwin Hospital 
spanning 2012–2019. Patients were referred 
to our clinic from general practitioners 
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or emergency physicians across multiple hospitals in 
South Australia, having presented with ‘possible’ or 
‘probable’ TIA symptoms. TIA clinic protocol included 
neuroimaging (diffusion weighted imaging (DWI), fluid- 
attenuated inversion recovery (FLAIR), susceptibility- 
weighted imaging (SWI)) prior to appointment, followed 
by review of clinical and radiological information by a 
neurovascular consultant neurologist.
All patients with either a history of cardiac surgery, 
(CABG and/or cardiac valve replacement) or MRI 
changes consistent with ‘probable CAA’ (as per the Modi-
fied Boston criteria) were identified. From this cohort, we 
reviewed patients in a consecutive fashion starting from 
2012. Patients with a history of valve replacement were less 
numerous, totalling 41 during this time period. We then 
compared these patients with 41 consecutively- identified 
patients with CAA and 41 with previous CABG. Several 
patients were excluded in this process in the setting of: 
(1) probable CAA diagnosed prior to cardiac surgery 
(n=3); (2) other potential causes for lobar- restricted 
CMBs (n=1); (3) non- compatible pacemaker device that 
precluded MRI (n=15); (4) refusal to have MRI (n=2) 
and (5) patients without cardiac surgery in whom MRI 
changes were reported by a radiologists as demonstrating 
‘probable CAA’, however, in whom on review had deep 
microbleeds precluding a diagnosis of CAA in accordance 
with the Modified Boston criteria (n=7).
Demographics, cardiovascular risk factors and cardiac 
procedure details were extracted from medical records. 
Follow- up was extracted from SA public hospital databases.
Data availability statement
Anonymised data will be shared by request from any qual-
ified investigator.
Neuroimaging
MRI was performed across four Adelaide sites (three 
major hospitals and one private imaging centre). The 
majority of scans were performed using a 3 Tesla machine 
(otherwise 1.5 Tesla) with equal representation of the 
three patient cohorts imaged in each machine. Scans 
were performed in the following order: 3- plane localiser; 
DWI; SWI; and FLAIR. GRE was not used. Either CT angi-
ography arch to vertex or MR angiography of intracra-
nial and extracranial vessel was performed in all patients. 
Images were independently reviewed (MDS and WV). 
Differences in final microbleed count and location were 
resolved by consensus.
CMBs were characterised as small, rounded, or circular, 
well- defined hypointense lesions within brain paren-
chyma with clear margins and a size of ≤10 mm on the 
SWI image.5 Microbleed mimics such as vessels, calci-
fication, partial volumes and haemorrhages within or 
adjacent to an infarct were carefully excluded. Further-
more, microbleeds seen in close proximity of infarcted 
tissue (acute or chronic) were excluded. We used a modi-
fied version of the Brain Observer Micro Bleed Scale 
to measure the presence, amount, and topographical 
distributions of CMBs in each subject.9 Only ‘certain’ 
CMBs were counted in this study. Microbleeds were cate-
gorised as cortical or juxta- cortical (includes subcortical 
microbleeds that touch the grey- white matter junction), 
subcortical white matter (SWM) (includes periventricular 
white matter and deep portions of the centrum semio-
vale), deep (includes any CMBs within the basal ganglia, 
thalamus, brainstem and internal or external capsules) 
and the cerebellum, see figure 1. Brain images were also 
examined for evidence of: (1) acute ischaemia or haem-
orrhage; (2) old areas of ischaemia or haemorrhage; 
(3) leukoaraiosis with severity rated using the modified 
Fazekas scale10 and (4) superficial siderosis.
Data collection and statistical analysis
Data are presented as mean (±SD) unless stated otherwise. 
Statistical analyses were performed using the SPSS (V.25; 
SPSS). Differences with a p<0.05 were considered to be 
statistically significant, without adjustment for multiple 
comparisons. Clinical demographic variables between the 
three patient cohorts were compared using Fisher’s exact 
test, t- test, or χ2 test as appropriate. Comparisons of CMBs 
between the CABG, valve replacement and CAA cohorts 
(total and location- based) were made using analysis of 
variance and Tukey’s Honestly Significant Difference 
tests. Similar methods were used to calculate statistical 
difference between the three groups for ratio of CMBs 
distributed within the SWM and cortex. We performed a 
receiver operating characteristic curve to assess the validity 
of ratio of CMB distribution in differentiating between 
underlying cause (cardiac surgery vs CAA) controlling for 
anticoagulation as a variable (warfarin or direct oral anti-
coagulant (DOAC)). Further analysis of the curve and a 
Mann- Whitney U test were used to generate the optimal 
ratio cut- off and area under the curve (AUC) respec-
tively. Inter- rater reliability was assessed by Cohen’s kappa 
Figure 1 Diagrams illustrating lobar and deep regions 
superimposed on MRI. Blue=cortex; red=subcortical white 
matter; green=deep matter (includes caudate head, lentiform 
nucleus, thalamic nucleus, internal and external capsule). 
Microbleeds abutting grey- white matter junction were 
classified as juxtacortical.
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coefficient with the kappa value interpreted as follows: 
κ<0.20 = poor, κ: 0.21–0.40=fair, κ: 0.41–0.60=moderate, 
κ: 0.61–0.80=good, κ: 0.81–1.0=very good.11 12
RESULTS
Patient demographics
One hundred and twenty- three patients were analysed; 41 
post- CABG (33%), 41 post- valve replacement (33%), of 
which 15 were mechanical (37 %) and 26 tissue (63%); 
and 41 patients with a history of CAA (33%). The majority 
of patients were male (61%) with a mean age 74±12 years. 
Patient characteristics are detailed in table 1.
The three cohorts were matched for sex, cogni-
tive impairment and cardiovascular risk factors. Valve 
replacement patients were younger than CABG and CAA 
patients (p=0.01). Antiplatelet/anticoagulation therapy 
was significantly different between the three groups 
(p=<0.01). Predictably, a higher proportion of valve 
replacement patients were on warfarin therapy, including 
all patients with mechanical valves. Target INR was not 
reliably recorded.
The prevalence of atrial fibrillation among the three 
groups was as follows: CABG n=3 (7%), valve n=9 (22%) 
and CAA n=6 (15%), p=0.18. Forty of the 123 patient 
cohort (33%) seen in the TIA clinic had an acute symp-
tomatic MRI lesion. The majority were ischaemic (35/40; 
88%) and evenly spread across the three groups (CABG 
15, valve 9, CAA 11). The remaining 5 (12%) were acute 
convexity subarachnoid haemorrhage, all of whom had 
background CAA. Of the remaining 83 patients, final 
TIA clinic diagnosis was TIA (n=14; 17%), migraine aura 
with or without headache (n=18; 22%), seizure (n=4; 
5%), non- neurological cause (n=32; 39%) and transient 
neurological focal episodes (TNFEs) in the setting of 
CAA (n=15; 18%). The prevalence of such TNFEs within 
the CAA cohort was 37%, manifesting mostly as transient 
sensory, motor and speech deficits.
Evidence of previous stroke on FLAIR was seen in 43% 
(n=53) of the patient cohort with an even spread across 
the three groups (CABG 18, valve 20, CAA 16; p>0.35). 
These strokes were ischaemic in all 38 cardiac surgery 
patients. Among the CAA cohort, 11/16 (69%) were isch-
aemic and 5/16 (31%) past lobar macrohaemorrhage.
Evaluation of CMBs
Inter-rater reliability
There was a statistically significant agreement between 
the two investigators with a kappa value of 0.82, indi-
cating ‘very good’ interrater reliability (95% CI 0.61 to 
0.98, p<0.01).
CABG versus valve replacement
The frequency, numbers and topographic distribution of 
CMBs are listed in table 2. CMBs were more prevalent 
in patients post- valve replacement surgery compared with 
post- CABG (90 vs 51%, p<0.01) and average microbleed 
burden was greater (3.9±3.3 vs 1.8±2.3 respectively; 








Age (years) 77±10 76±11 69±13 0.005
Sex (females) 21 (51%) 11 (27%) 16 (39%) 0.12
Hypertension 26 (63%) 34 (83%) 31 (76%) 0.12
Diabetes mellitus 7 (17%) 16 (39%) 12 (29%) 0.09
Smoking history 15 (36%) 17 (41%) 19 (46%) 0.65
Antithrombotic therapy 21 (54%) 38 (93%) 40 (98%) <0.01
  Single antiplatelet 19 (46%) 32 (78%) 12 (29%) <0.01
  Dual antiplatelet 1 (2%) 3 (7%) 3 (7%) 0.55
  Warfarin 0 1 (2%) 19 (46%) <0.01
  DOAC 2 (4%) 2 (5%) 6 (15%) 0.18
Past ischaemic stroke 11 (27%) 18 (44%) 20 (48%) 0.35
Past haemorrhagic stroke 5 (12%) 0 0 <0.05
Cognitive impairment 6 (15%) 2 (5%) 2 (5%) 0.18
Values are mean±SD or expressed as percentage.
CABG, coronary artery bypass grafting; DOAC, direct oral anticoagulant.
Table 2 Prevalence and distribution of microbleeds 
between CABG and valve replacement patients
CABG (n=41) Valve (n=41) P value
Prevalence 51% 90% <0.01
Total 1.8±2.3 3.9±3.3 0.01
Cortical 1.0±1.4 2.6±2.7 0.01
SWM 0.4±0.9 0.8±1.3 0.16
CABG, coronary artery bypass grafting; SWM, subcortical white 
matter.
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p=0.01). Valve replacement subtype (mechanical vs 
tissue) did not impact CMB burden (mechanical valves 
n=15, 3.7±2.8 vs tissue n=26, 3.6±3.4; p=0.94). In the total 
non- CAA cohort, DOAC use was associated with higher 
CMB burden (n=6, 7.3±4.1) compared with warfarin 
(n=20, 4.0±3.1; p=0.02.)
Within both cardiac surgery cohorts there was a lobar 
predominant pattern of microbleed distribution. A lobar- 
restricted pattern was seen in 26 of the 37 CMB positive 
patients post- valve replacement (70%) and 14 of the 21 
microbleed- positive CABG cohort (67%) p=0.81. In 8 of 
these patients (four post- CABG, four postvalve) only a 
single microbleed was evident. A mixed (lobar and deep) 
pattern was seen in 30% of valve replacement patients 
(11/37) and 33% of CABG patients (7/21; (p=0.81)). 
Furthermore 12/18 (15% of the post- surgery cohort) 
were lobar predominant (defined as ratio of cortical/
juxtacortical/subcortical CMBs to deep CMBs >2:1), 
see table 2. The majority of microbleeds were located 
within the cortical/juxtacortical tissue (valve replace-
ment: 2.6±2.7, 64% of total; CABG 1±1.4, 56% of total). 
A smaller, yet significant proportion were located within 
the SWM (valve replacement: 0.8±1.3, 19% of total; 
CABG 0.4±0.9, 25% of total), see figure 2. There was a 
higher prevalence of cortical/juxta- cortical CMBs in valve 
replacement patients (p=0.01), however, no significant 
difference for frequency of microbleeds within the SWM 
(p=0.16) or deep grey matter (p=0.17).
Subanalysis of solely patients who were microbleed posi-
tive showed no significant difference for total number of 
microbleed between the valve replacement and CABG 
groups (4.2±4.1 vs 3.5±2.3, p=0.99). Similarly, there was 
no significant difference in local CMB burden between 
CMB positive valve replacement and CABG cohorts, 
whether (1) strictly cortical (2.7±2.7 vs 2.0±1.0; p=0.98), 
(2) SWM (0.8±1.3 vs 0.9±0.9; p=0.99); and (3) cerebellar 
(0.3±0.6 vs 0.2±0.6; p=0.9).
CAA versus CABG/valve replacement
Almost by definition, all patients with CAA had 
microbleeds evident on imaging. In comparison with the 
CMB positive valve replacement cohort, CMB burden 
was higher (18.0±25.9 vs 4.2±4.1 respectively; p<0.01) 
including strictly cortical burden (15.5±20.4 vs 2.7±2.7, 
respectively; p<0.01). Findings were similar in compar-
ison with CMB positive CABG patients (18.0±25.9 vs 
3.5±2.3 for total burden (p<0.01) and 15.2±20.4 vs 2.0±1.0 
for strictly cortical CMB burden (p<0.01). Contrastingly, 
there was no significant differences in SWM CMB burden 
(CAA patients 1.5±3.0 vs 0.8±1.3 CMB positive valve 
replacement patients (p=0.74) and (0.9±0.9) in CMB 
positive CABG patients (p=0.87)), see table 3. A greater 
proportion of the total microbleed burden was located 
within the SWM among the CMB positive cardiac surgery 
cohort (valve replacement 19%, CABG 25%) compared 
with patients with CAA (7%).
Superficial siderosis was identified in 20/41 (45%) 
patients with CAA. Contrastingly, superficial siderosis was 
not identified in any post- cardiac surgery patient.
Boston criteria ‘false positivity’ and CMB location ratio
In total, 32 (39%) of the 82 post- cardiac surgery patients 
met both clinical and radiological Modified Boston 
Criteria for ‘probable CAA’. While target INR or antico-
agulation fluctuation was not recorded, sixteen of these 
Figure 2 Susceptibility- weighted imaging from a valve 
replacement patient demonstrating lobar and subcortical 
white matter microbleeds. (A) Microbleed within the frontal 
cortex; (B) Microbleed within the subcortical white matter. 
White arrows point to microbleed.
Table 3 Correlation between topographic distribution of microbleeds and underlying medical history significant for either 
CABG, valve replacement or CAA
Amyloid (n=41) CABG (n=21) Valve (n=37) P value* CABG- Amyloid† Valve- Amyloid† Valve- CABG†
Total CMB 18.0±25.9 3.5±2.3 4.1±4.1 <0.01 <0.01 <0.01 0.99
Cortical 15.5±20.4 2.0±1.0 2.7±2.7 <0.01 <0.01 <0.01 0.98
SWM 1.5±3.0 0.9±0.9 0.8±1.3 0.74 0.87 0.74 0.99
Ratio‡ 0.05±0.08 0.26±0.28 0.18±0.17 <0.01 <0.01 0.01 0.25
*P value calculated using ANOVA.
†P value calculated using Tukey honest significant difference test.
‡Ratio=SWM/SWM+cortical microbleeds.
ANOVA, analysis of variance; CAA, cerebral amyloid angiopathy; CABG, coronary artery bypass grafting; CMB, cerebral microbleeds; SWM, 
subcortical white matter.
5De Sciscio M, et al. BMJ Neurol Open 2021;3:e000166. doi:10.1136/bmjno-2021-000166
Open access
patients (50%) were anticoagulated (warfarin n=10 or 
DOAC n=6). CMB burden did not differ between groups 
(anticoagulated 4.1±2.5; non- anticoagulated 3.8±1.5), 
suggesting that anticoagulation does not explain this 
association.
As we had determined that SWM CMB proportions 
were higher in cardiac surgery patients than those with 
CAA, we set out to identify whether a distribution ratio 
would allow for differentiation. The ratio of SWM:strictly 
cortical CMBs was substantially lower in CAA patients 
than CMB positive valve replacement (0.05±0.08 vs 
0.18±0.17; p=0.01) or CABG (0.05±0.08 vs 0.26±0.28; 
p<0.01) patients (p=0.25 for comparison of the two 
cardiac surgery cohorts). We then analysed this ratio of 
microbleeds as a distinguishing variable. We found that 
a ratio of 0.45 was optimal in distinguishing underlying 
cause of microbleeds, as either in the setting of previous 
cardiac surgery or probable CAA, in patients presenting 
with asymptomatic CMBs with a sensitivity of 0.56 and 
specificity of 0.93 with an AUC=0.71.
Evaluation of white matter disease
A greater proportion of CAA patients showed severe white 
matter disease on MRI (n=16; 39%) compared with the 
valve replacement (n=5; 12%) and CABG (n=11; 27%) 
cohorts. The degree of white matter disease was associ-
ated with an increased number of CMBs (online supple-
mental file 1).
DISCUSSION
CMB frequency and location
Our retrospective dual centre cohort study demonstrated 
that lobar restricted microbleeds are seen in the majority 
of patients with a past history of cardiac surgery, who 
presented to our TIA clinic. Further, the majority of these 
met diagnostic criteria for CAA. However, the pattern of 
microbleed distribution differed from that of CAA, with 
proportionally greater CMB burden in the SWM.
The findings of our study are consistent with those 
of previous acute post- cardiac surgery studies,6 7 and, 
together with these studies, strongly suggests that cardiac 
surgery is a cause of lobar- restricted microbleeds, which 
persist chronically. In a recent study, new SWI- detected 
CMBs were seen acutely postcardiac surgery in 76% 
(57/75) of patients in a lobar- predominant distribu-
tion (>90% of total microbleeds). A third of this cohort 
developed >5 new microbleeds.7 Similarly to our study, 
incidence of post- operative CMBs was higher in patients 
post valve replacement (86%) than post- CABG (58%), 
mirroring our findings (90% vs 51%, respectively).7 This 
study also confirmed that a proportion of these inci-
dental microbleeds can involve the deep matter (18/295 
total microbleeds).7 As such, most postcardiac surgery 
microbleeds are strictly cortical, but the deep white 
matter is not uncommonly involved.
We found that 39% of our cardiac surgery patients met 
the Modified Boston Criteria for the diagnosis of probable 
CAA, and that this was not explained by use of antico-
agulation. Such patients are therefore vulnerable to the 
misdiagnosis of CAA based on radiological changes alone. 
However, we also identified that a greater proportion of 
the lobar microbleeds were localised to the deep white 
matter compared with microbleeds seen in the probable 
CAA cohort. Therefore, a distribution ratio assessing the 
proportion of microbleeds within the deep white matter 
to that of total cortical microbleeds provides reasonable 
sensitivity and specificity for distinguishing between CMBs 
secondary to CAA compared with past valvular surgery or 
CABG. It may help provide reassurance if such patients 
require anticoagulation or thrombolysis. Further reassur-
ance may be given by the absence of severe white matter 
disease, and in particular superficial siderosis, which was 
seen in zero of our postcardiac surgery patients. Further 
revision of the Boston Criteria for diagnosing CAA could 
be considered to exclude patients with a history of cardiac 
bypass surgery.
Mechanisms of CMB formation
The underlying mechanism of microbleed formation 
during cardiac surgery remains unclear. The most 
commonly proposed explanation is microembolisa-
tion of debris from either cross- clamping of the aorta 
or manipulation of a calcified valve,6 supported by the 
increased incidence in patients undergoing valve replace-
ment.6 7 Although length of time on bypass is another 
correlation.6 7 Our study is potentially consistent with 
both explanations. We also showed that among our 
cardiac surgery patients meeting the Boston Criteria for 
CAA, there was no statistical difference in microbleed 
burden based on anticoagulation use, thus suggesting 
that the formation of microbleeds was unlikely a result of 
anticoagulation and more consistent with an intraopera-
tive cause.
Anticoagulation use
The safety of anticoagulation in patients with asymptom-
atic CMBs remains undetermined.13 In particular, results 
from the CROMIS-2 study showed that despite previous 
findings of increased microbleed burden being associated 
with greater haemorrhagic complications with long- term 
anticoagulation, the presence of CMBs is not a contra-
indication for anticoagulation.14 As such, an evidence- 
based approach to the safe management of patients with 
asymptomatic CMBs requiring long- term anticoagulation 
remains lacking. Larger observational cohort analyses to 
refine risk prediction based on the underlying cause of 
CMB are warranted. However, combining the results of 
our study with the acute post- surgery MRI study of Patel et 
al, it seems likely that CMBs following cardiac surgery are 
chronic and do not entail an elevated risk of antithrom-
botic treatments.
Limitations
This study had several limitations. First, our study was a 
convenience sample of patients presenting with transient 
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neurological symptoms to neurovascular clinics. Thus, 
our study may not be representative of the broader popu-
lation of patients with a remote past history of either 
cardiac surgery or CAA. In addition, our findings of a 
distribution ratio able to differentiate underlying CMB 
pathology requires further validation among an indepen-
dent cohort of patients.
Second, we did not collect data on target INR or its vari-
ability post cardiac surgery which may have impacted on 
the incidence of microbleeds among some patients (ie, 
in the setting of sub or supratherapeutic INR). However, 
a similar CMB distribution pattern was evident in non- 
anticoagulated postcardiac surgery patients.
Third, this retrospective study was not designed or 
powered to assess subsequent rates of symptomatic ICH 
among the 3 groups of patients, nor was longitudinal 
stability of CMBs in cardiac surgery patients assessed. 
Future longitudinal observational studies are therefore 
needed.
Finally, given the lack of baseline MRI prior to cardiac 
surgery, we were unable to identify cases of subclinical 
CAA that may have otherwise been allocated to the post- 
cardiac surgery cohort but with pre- existing microbleeds.
CONCLUSION
Lobar restricted or predominant CMBs are a common 
finding in patients with a history of past cardiac surgery. 
A significant proportion of these patients meet clinical 
and radiological Modified Boston Criteria for ‘probable’ 
CAA. This may lead to an incorrect diagnosis and dele-
teriously alter antithrombotic management. However, we 
found that lobar CMBs in cardiac surgery patients were 
relatively more common within the SWM, and that a 
distribution ratio of SWM:SWM/cortical microbleeds is 
reasonably accurate in differentiating the underlying asso-
ciation as either CAA or past cardiac surgery. These find-
ings warrant further investigation among an independent 
cohort of patients to validate our proposed threshold for a 
distribution ratio abling to differentiate underlying CMB 
pathology. If proven, the modified Boston criteria could 
be further modified to exclude patients with previous 
cardiac valve replacement or CABG and multiple lobar 
microbleeds.
Finally, larger observational studies are needed to 
better delineate pathophysiology and therapeutic impli-
cations, especially clarifying the temporal development 
and longer- term stability of cardiac surgery- associated 
microbleeds, and providing further reassurance that 
these patients are not at elevated ICH risk with either 
antithrombotic or thrombolytic treatments.
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